UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange act of 1934
Date of report (date of earliest event reported): February 21, 2015
RECEPTOS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-35900 | | 26-4190792 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
3033 Science Park Road, Suite 300
San Diego, California 92121
(858) 652-5700
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01. | Regulation FD Disclosure. |
On February 21, 2015, Receptos, Inc. (the “Company”) reviewed in further detail the data from the induction period of its TOUCHSTONE trial, the Company’s Phase 2 study of ozanimod (RPC1063) in Ulcerative Colitis, in a presentation at a meeting of the European Crohn’s and Colitis Organization in Barcelona, Spain. The slides used at the presentation are furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The Company does not undertake to update this presentation.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Slide presentation of Receptos, Inc. dated February 21, 2015. |
The information in this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| Date: February 23, 2015 | | | | RECEPTOS, INC. |
| | | |
| | | | By: | | /s/ Christian Waage |
| | | | | | Christian Waage |
| | | | | | SVP & General Counsel |
3
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Corporate slide presentation of Receptos, Inc. dated February 21, 2015. |
